Drug
RP L301
RP L301: highest development phase Phase 2, developed by Rocket Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Rocket Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| RP-L301 NCT06422351 | Phase 2 | Pyruvate Kinase Deficiency |
| RP-L301 NCT04105166 | Phase 1 | Pyruvate Kinase Deficiency |
Latest
No recent events.
Follow RP L301 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.